COST-EFFECTIVENESS OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VERSUS ACLIDINIUM/FORMOTEROL (ACL/ FOR) IN PATIENTS WITH COPD IN THE UNITED KINGDOM

被引：0
|
作者：
Shah, D. [1 ]
Martin, A. [2 ]
Kendall, R. [3 ]
Noorduyn, S. G. [4 ]
Dasari, P. [5 ]
Risebrough, N. [6 ]
Ismaila, A. [7 ]
机构：
[1] ICON plc, Jersey City, NJ USA
[2] GSK, Brentford, England
[3] ICON Plc, Vancouver, BC, Canada
[4] GSK, Value Evidence & Outcomes, Mississauga, ON, Canada
[5] ICON Plc, Houston, TX USA
[6] ICON Plc, Toronto, ON, Canada
[7] GSK, Value Evidence & Outcomes, Collegeville, PA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE708
引用
收藏
页码：S190 / S191
页数：2
相关论文
共 50 条
  • [21] An Analysis of the IMPACT Trial Assessing Single-Inhaler Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI Using a Composite Adverse Event Outcome in Patients with COPD
    Wells, J. M.
    Bhatt, S. P.
    Carr, T. F.
    Criner, G. J.
    Halpin, D. M. G.
    Han, M. K.
    Jain, R.
    Kaye, M. G.
    Kraft, M.
    Lipson, D. A.
    Mapel, D.
    Mammen, M. J.
    McEvoy, C.
    Midwinter, D.
    Singh, D.
    Wise, R.
    Dransfield, M. T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [22] COST-EFFECTIVENESS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS TIOTROPIUM MONOTHERAPY IN PATIENTS WITH COPD IN THE UK
    Martin, A.
    Shah, D.
    Shukla, S.
    Kendall, R.
    Risebrough, N. A.
    Compton, C.
    Ismaila, A.
    VALUE IN HEALTH, 2022, 25 (01) : S40 - S40
  • [23] INFORMING THE PATHWAY OF COPD TREATMENT (THE IMPACT STUDY): SINGLE INHALER TRIPLE THERAPY (FF/UMEC/ VI) VERSUS FF/ VI IN PATIENTS WITH COPD - COST-EFFECTIVENESS IN THE UK
    Martin, A.
    Shah, D.
    Schroeder, M.
    Ndirangu, K.
    Risebrough, N.
    Anley, G.
    Okorogheye, G.
    Fenwick, E.
    Ismaila, A. S.
    THORAX, 2018, 73 : A237 - A237
  • [24] Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China
    Lan, Ying
    Yang, Nan
    Wang, Yirong
    Yang, Yujie
    Xu, Min
    He, Qin
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 609 - 619
  • [25] Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
    Mannino, David
    Bogart, Michael
    Germain, Guillaume
    Huang, Shirley P.
    Ismaila, Afisi S.
    Laliberte, Francois
    Jung, Young
    MacKnight, Sean D.
    Stiegler, Marjorie A.
    Duh, Mei Sheng
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 491 - 504
  • [26] UMECLIDINIUM/VILANTEROL (UMEC/VI) COMPARED WITH TIOTROPIUM (TIO) FOR TIME-TO-FIRST INPATIENT ADMISSION AMONG PATIENTS WITH COPD IN A MANAGED CARE POPULATION
    Slade, David
    Ray, Riju
    Moretz, Chad
    Germain, Guillaume
    Laliberte, Francois
    Shen, Qin
    Duh, Mei Sheng
    MacKnight, Sean
    Hahn, Beth
    CHEST, 2020, 158 (04) : 1716A - 1717A
  • [27] UMECLIDINIUM/VILANTEROL (UMEC/VI) VERSUS MONO-BRONCHODILATOR THERAPY IN STEROID-FREE GOLD B PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): THE EMAX TRIAL
    Jones, P. W.
    Maltais, F.
    Kerwin, E.
    Bjermer, L.
    Watkins, M. L.
    Tombs, L.
    Naya, I.
    Boucot, I.
    Lipson, D.
    Compton, C.
    THORAX, 2018, 73 : A235 - A236
  • [28] THE IMPACT TRIAL: COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS DUAL BRONCHODILATOR THERAPY (UMEC/VI) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN
    Vallejo-Aparicio, L. A.
    Paly, V. F.
    Schroeder, M.
    Martin, A.
    Risebrough, N.
    Abreu, C.
    Biswas, C.
    Izquierdo Alonso, J. L.
    Riesco Miranda, J. A.
    Soler Cataluna, J. J.
    Ismaila, A. S.
    VALUE IN HEALTH, 2019, 22 : S878 - S878
  • [29] COST-EFFECTIVENESS OF BUDESONIDE/FORMOTEROL VERSUS FLUTICASONE/SALMETEROL BASED ON REAL-WORLD EFFECTIVENESS IN PATIENTS WITH COPD
    Hedegaard, M.
    Janson, C.
    Lisspers, K.
    Stallberg, B.
    Johansson, G.
    Jorgensen, L.
    Larsson, K.
    VALUE IN HEALTH, 2012, 15 (07) : A563 - A563
  • [30] Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma
    Rutten-van Mölken, MPMH
    van Doorslaer, EKA
    Till, MD
    PHARMACOECONOMICS, 1998, 14 (06) : 671 - 684
12345